Plans to set up two new plants, market a new technology. Actis Biologics (ABPL), the Indian arm of US-based biotech drug discovery company Actis Biologics Inc, plans to raise about $30 million by selling stake to a clutch of private equity players to build two new plants and market a new process that will help other drug makers cut cost. The company will sell a 15 per cent stake to US- and Europe-based leading private equity investors, Sanjeev Saxena, chairman and founder, ABPL, said. The sale may be completed in the next four weeks. Leading biotechnology companies such as Biocon and Avesthagen are selling stakes to private equity players and other investors to raise money to discover new potential drugs that can be self-marketed or out-licensed to multinational pharmaceutical and biotech companies, such as Pfizer, Roche, Astra Zeneca and Amgen. […]